| Literature DB >> 35130502 |
Peter L Greenberg1, Richard M Stone2, Aref Al-Kali3, John M Bennett4, Uma Borate5, Andrew M Brunner6, Wanxing Chai-Ho7, Peter Curtin8, Carlos M de Castro9, H Joachim Deeg10, Amy E DeZern11, Shira Dinner12, Charles Foucar13, Karin Gaensler14, Guillermo Garcia-Manero15, Elizabeth A Griffiths16, David Head17, Brian A Jonas18, Sioban Keel10, Yazan Madanat19, Lori J Maness20, James Mangan21, Shannon McCurdy22, Christine McMahon23, Bhumika Patel24, Vishnu V Reddy25, David A Sallman26, Rory Shallis27, Paul J Shami28, Swapna Thota29, Asya Nina Varshavsky-Yanovsky30, Peter Westervelt31, Elizabeth Hollinger32, Dorothy A Shead32, Cindy Hochstetler32.
Abstract
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts meets on an annual basis to update the recommendations. These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.Entities:
Mesh：
Year: 2022 PMID： 35130502 DOI： 10.6004/jnccn.2022.0009
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908